| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -11,610 | -27,120 | -13,280 | -9,810 | -4,740 |
| Net Income Growth | +57.19% | -104.22% | -35.37% | -106.96% | unch |
Anchiano Therapeutics Ltd ADR (ANCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapies to treat cancer. The company's product candidate, inodiftagene vixteplasmid, is in development as a treatment for non-muscle-invasive bladder cancer. It operates primarily in Cambridge, MA and Jerusalem, Israel. Anchiano Therapeutics Ltd. is based in CAMBRIDGE.